Navigation Links
Ground-breaking Research Identifies Molecular Subtyping as a Key to Determining Prognosis and Benefit of Chemotherapy for Breast and Colorectal Cancers
Date:5/31/2013

IRVINE, Calif., May 31, 2013 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that results from five studies focused on breast, colon and colorectal cancer will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 31-June 4, 2013 at McCormick Place in Chicago. Of particular importance are the studies which demonstrate that molecular subtyping allows for improvement in therapy selection and overall patient survival. 

The posters covering breast cancer include:

  • Effectiveness of MammaPrint® and BluePrint® in identifying molecular subtypes of breast tumors as a predictor for tumor response to targeted chemotherapies.
  • MammaPrint MINT study assesses the ability of molecular profiling and traditional pathologic and clinical prognostic factors to predict patient response to neo-adjuvant chemotherapy.
  • Genomic profiling of breast cancer in African American women.

"It is clear that molecular subtypes are key pieces of information in determining the best course of treatment for breast cancer patients, and that subtyping will only become more important as hundreds of targeted therapies reach the market in the coming decade," said Agendia CEO David Macdonald .

The posters/discussions covering colorectal and colon cancer include:

  • Intrinsic subtypes of colorectal cancer that direct different treatment strategies.
  • The use of ColoPrint® as a predictor of outcome and chemotherapy benefit in stage II and III colon cancer patients.

"Like breast cancer, where molecular classification into subtypes has clear relevance for prognosis and treatment, we are finding clinically relevant subtypes for colorectal and colon cancer," Macdonald added. "Agendia has a rich history of presenting innovative and ground-breaking research that benefits oncologists and their cancer patients."

A more complete list of presentation abstracts can be found on ASCO's website at www.asco.org.

About Agendia:
Agendia is a leading molecular diagnostic company that develops and markets FFPE-based genomic diagnostic products. Agendia's breast cancer Symphony suite was developed by analyzing the complete human genome, ensuring 100% definitive results for cancer patients. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.

In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development. The Company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.  For more information, please visit www.agendia.com.


'/>"/>
SOURCE Agendia
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Convergence Pharmaceuticals Announces Successful Interim Data from Ground-Breaking Phase II Trigeminal Neuralgia Study
2. Lilly Statement on Indiana Biosciences Research Institute
3. Breast Cancer Imaging Market: US, EU, South America Analysis & Forecast Research Reports
4. New Research Shows Continuing Medical Education Saves Healthcare Costs
5. Alzheimer Market: Drugs, Therapeutics & Diagnostics Research Reports
6. Cempra Awarded $58 Million Contract to Develop Antibiotic for Pediatric Use and Biodefense by Biomedical Advanced Research and Development Authority (BARDA)
7. International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma
8. Clinical Team Researching the Impact of the EarlySense System Wins Best Novel Idea Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference
9. Lupus Research Institute Hosts First International Conference to Advance New Treatments for Lupus Nephritis
10. Research-based Pharmaceutical Industry Launches Do You Mind? Campaign to Fight Mental and Neurological Disorders
11. Claret Medical, Inc. Announces Publication of the First Clinical Research on the Frequency and Composition of Embolic Debris Captured during TAVR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... 2017  As the latest Obamacare repeal effort moves ... (R-LA) and Lindsey Graham (R-SC) medical ... device industry is in an odd place.  The industry ... excise tax on medical device sales passed along with ... patients, increased visits and hospital customers with the funding ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., a ... today announced that it has been ranked #1 by its ... Book™ Rankings 2017 User Survey. ZirMed was recognized as ... large hospitals and medical centers over 200 beds and holds ... healthcare technology user survey history. ...
(Date:9/13/2017)... Sept. 13, 2017   OrthoAtlanta has been named ... Football Host Committee (AFHC) for the 2018 College Football Playoff ... 2018, at Mercedes-Benz Stadium in Atlanta, Georgia ... AFHC "I,m In" campaign, participating in many activities leading up ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one ... an innovative new design of the shoulder pad. The shoulder pad provides optimal ... controlling your pain while using cold therapy. By utilizing ice and water that is ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
Breaking Medicine News(10 mins):